Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 2
1999 4
2000 7
2001 8
2002 9
2003 18
2004 27
2005 42
2006 47
2007 87
2008 88
2009 120
2010 139
2011 145
2012 161
2013 170
2014 175
2015 171
2016 158
2017 145
2018 137
2019 98
2020 101
2021 95
2022 72
2023 66
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

2,023 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Vorinostat as potential antiparasitic drug.
Herrera-Martínez M, Orozco-Samperio E, Montaño S, Ariza-Ortega JA, Flores-García Y, López-Contreras L. Herrera-Martínez M, et al. Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7412-7419. doi: 10.26355/eurrev_202007_21909. Eur Rev Med Pharmacol Sci. 2020. PMID: 32706080 Free article. Review.
Vorinostat for treatment-refractory bullous pemphigoid.
Blanchard G, Solly F, Basset V, Fontao L, Blanchard M, Guenova E. Blanchard G, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1218-e1220. doi: 10.1111/jdv.19209. Epub 2023 Jun 8. J Eur Acad Dermatol Venereol. 2023. PMID: 37191129 No abstract available.
Infant brain tumor trials: Beyond feasibility.
Bouffet E, Lafay-Cousin L. Bouffet E, et al. Neuro Oncol. 2022 Jul 1;24(7):1191-1192. doi: 10.1093/neuonc/noac065. Neuro Oncol. 2022. PMID: 35287175 Free PMC article. No abstract available.
Vorinostat in cutaneous T-cell lymphoma.
Duvic M, Vu J. Duvic M, et al. Drugs Today (Barc). 2007 Sep;43(9):585-99. doi: 10.1358/dot.2007.43.9.1112980. Drugs Today (Barc). 2007. PMID: 17940636 Review.
2,023 results